| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5701299 | European Journal of Surgical Oncology (EJSO) | 2017 | 14 Pages |
Abstract
Our study suggests oxaliplatin offers a survival advantage over MMC when used for HIPEC in CRC PC. Further studies to understand its efficacy, complications and ideal preparation are required. A Phase III randomised control trial comparing oxaliplatin and MMC would enhance decision-making.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
V. Leung, Y.R. Huo, W. Liauw, D.L. Morris,